### In vitro / physico-chemical Data <a id="invitro-and-physico-chemical-data"></a>

A literature search was performed to collect available information on physicochemical properties of moxidectin. The obtained information from literature is summarized in the table below. 

| **Parameter**   | **Unit** | **Value** | Source                                     | **Description**                                 |
| :-------------- | -------- | --------- | ------------------------------------------ | ----------------------------------------------- |
| MW              | g/mol    | 639.83          | [Drugbank](#main-references)               | Molecular weight                                |
| pK<sub>a</sub>  | - (neutral)         |           | [Wood 2024](#main-references)         | Acid dissociation constant                      |
| Solubility (pH 7) | mg/mL         | 5.20E-3          | [Drugbank](#main-references)               | Aqueous Solubility, FaSSIF, ...                 |
| logP            |          | 6          | [Drugbank](#main-references) (experimental) | Partition coefficient between octanol and water |
| logP            |          | 5.3          | [Drugbank](#main-references) (predicted) | Partition coefficient between octanol and water |
| logP            |          | 5.67          | [Wood 2024](#main-references) (predicted) | Partition coefficient between octanol and water |
| logP            |          | 4.3          | [Pubchem](#main-references) (predicted) | Partition coefficient between octanol and water |
| fu              |         | 0.00078          | [Wood 2024](#main-references)                | Fraction unbound in plasma                      |
| CLint CYP3A4            | ÂµL/min/mg protein         | 36          | [Wood 2024](#main-references) (predicted) | Intrinsic clearance mediated by CYP3A4 |

### Clinical Data  <a id="clinical-data"></a>

A literature search was performed to collect available clinical data on moxidectin in healthy adults.

#### Model Building <a id="model-building"></a>

The following studies were used for model building (training data):

| Publication                 | Arm / Treatment / Information used for model building |
| :-------------------------- | :---------------------------------------------------- |
| [Korth-Bradley 2012a](#main-references) | Healthy Subjects with a single oral dose of 10 mg solution in fasted or fed conditions           |
| [Korth-Bradley 2012b](#main-references) | Healthy Subjects with a single oral dose of 10 mg solution or tablet           |

#### Model Verification <a id="model-verification"></a>

The following studies were used for model verification:

| Publication                 | Arm / Treatment / Information used for model building |
| :-------------------------- | :---------------------------------------------------- |
| [Cotreau 2003](#main-references) | Healthy Subjects with a single oral dose of 3 mg, 9 mg, 18 mg or 36 mg in fasted or fed conditions|
| [Kinrade 2018](#main-references) | Healthy Subjects with a single oral dose of 4 mg, 8 mg, 16 mg, 24 mg, 36 mg in fasted conditions      |

